Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Real Time Quote from BATS)

$14.04 USD

14.04
3,998,393

-0.04 (-0.28%)

Updated May 3, 2024 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

LabCorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Ongoing sales rebound in the base business for both Diagnostics and Drug Development segments is likely to have benefited LabCorp (LH) in Q1.

Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate

by Zacks Equity Research

Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.

Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?

by Zacks Equity Research

Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) and Diabetes arm are boosting business in recent months.

Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why

by Zacks Equity Research

Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Macro Headwinds

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down

by Zacks Equity Research

TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.

Is Teva Pharmaceutical Industries (TEVA) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.

TEVA Shares Rise on Broad Support for Opioids Settlement

by Zacks Equity Research

With the required participation from states and local governments, TEVA can now move forward with the nationwide settlement.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Jumps 5.5%: Will It Continue to Soar?

by Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.

Teva Pharmaceutical (TEVA) Names Richard Francis as New CEO

by Zacks Equity Research

Teva Pharmaceutical (TEVA) appoints Richard Francis as the company's new president and chief executive officer, effective from Jan 1, 2023.

TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down

by Zacks Equity Research

TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.

Kinjel Shah headshot

Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More

by Kinjel Shah

Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel

by Zacks Equity Research

Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure

by Sundeep Ganoria

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision

by Zacks Equity Research

Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.

TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B

by Zacks Equity Research

TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

by Zacks Equity Research

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention

by Zacks Equity Research

With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.

Why Is Bausch (BHC) Down 11.2% Since Last Earnings Report?

by Zacks Equity Research

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View

by Zacks Equity Research

TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.

Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

by Zacks Equity Research

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA

by Zacks Equity Research

Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.